Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Cwbr crawled time : 13:15 save search
CohBar to Announce 2021 Third Quarter Financial Results and Provide Business Update on November 15, 2021
Published: 2021-11-01 (Crawled : 13:15) - globenewswire.com
CWBR | $0.8006 -11.88% 3.8K
|
Health Technology
|
| O: 4.84%
H: 5.69%
C: 3.02%
financial results results
CohBar Announces CB4211 Phase 1a/1b Results Selected for Late Breaker Presentation at The Liver Meeting® 2021
Published: 2021-10-13 (Crawled : 13:15) - globenewswire.com
CWBR | $0.8006 -11.88% 3.8K
|
Health Technology
|
| O: -2.16%
H: 4.55%
C: 0.65%
presentation phase 1 results liver phase 1b
CohBar Granted U.S. Patent Covering CB4211 Compositions and Use for Treating Nonalcoholic Steatohepatitis (NASH)
Published: 2021-09-08 (Crawled : 13:15) - globenewswire.com
CWBR | $0.8006 -11.88% 3.8K
|
Health Technology
|
| O: -1.63%
H: 6.12%
C: 5.79%
hepatitis patent nash granted grant
CohBar Provides Update on the Phase 1a/1b Clinical Trial for CB4211 Under Development for NASH and Obesity
Published: 2021-07-14 (Crawled : 13:15) - globenewswire.com
CWBR | $0.8006 -11.88% 3.8K
|
Health Technology
|
| O: -7.97%
H: 0.0%
C: -11.02%
obesity phase 1 nash trial phase 1b
CohBar to Announce 2021 First Quarter Financial Results and Provide Business Update on May 17, 2021
Published: 2021-05-03 (Crawled : 13:15) - globenewswire.com
CWBR | $0.8006 -11.88% 3.8K
|
Health Technology
|
| O: -2.99%
H: 6.15%
C: 3.85%
financial results results
CohBar Appoints Joseph J. Sarret, M.D., J.D. as Chief Executive Officer and DirectorAnnounces change to the Board of Director’s Chair
Published: 2021-04-27 (Crawled : 13:15) - biospace.com/
CWBR | $0.8006 -11.88% 3.8K
|
Health Technology
|
| O: 1.45%
H: 0.0%
C: -7.14%
CDXS | $2.76 1.1% -0.74% 420K
|
Process Industries
|
| O: 0.0%
H: 1.6%
C: -2.2%
CohBar Completes Last Subject Visit in the Phase 1b Clinical Trial for CB4211 Under Development for NASH and Obesity
Published: 2021-04-21 (Crawled : 13:15) - globenewswire.com
CWBR | $0.8006 -11.88% 3.8K
|
Health Technology
|
| O: 0.92%
H: 7.27%
C: 5.45%
obesity phase 1 nash trial phase 1b phase 2b
CohBar to Present at the Mitochondria-Targeted Drug Development Summit
Published: 2021-04-14 (Crawled : 13:15) - globenewswire.com
CWBR | $0.8006 -11.88% 3.8K
|
Health Technology
|
| O: 0.0%
H: 5.72%
C: 0.82%
drug presentation
CohBar Completes Enrollment in the Phase 1b Clinical Trial for CB4211 Under Development for NASH and Obesity
Published: 2021-03-29 (Crawled : 13:15) - globenewswire.com
CWBR | $0.8006 -11.88% 3.8K
|
Health Technology
|
| O: 2.94%
H: 6.64%
C: -5.71%
obesity phase 1 nash trial phase 1b phase 2b enroll
Gainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 640K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.38 30.58% 23.42% 300K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Your saved searches
Save your searches and get alerts when important news are released.